PERMANENT AWARD EVIDENCE

SCI Cleanroom Cleaning 2025/26

NHS Blood and Transplant · published 9 Dec 2025. This page preserves the identifiers and current held fields for one Contracts Finder release; it is not an invoice, performance assessment or complete contract history.

Contracts Finder release IDb567c383-e23e-498e-858b-113f430021cb-875243
Open Contracting ID (OCID)ocds-b5fd17-9bda1be9-395c-457d-afcb-776ebdda9b2d
Buyer identifierGB-CFS-328517
Release typeplanning
PUBLISHED COMMERCIAL FIELDS

Values stay separate.

A tender estimate and an award value answer different questions. Neither is treated as cash paid.

Award value
Not disclosed
award field
Tender value
£350,000
tender field
Procurement method
Not stated
Category
services
CPV
90910000
Cleaning services
Delivery
United Kingdom
No postcode
PUBLISHED DESCRIPTION

What the notice says

The Cellular and Molecular Therapies (CMT) function is a Specialist Services department forming part of NHS Blood and Transplant (NHSBT) Therapeutic Services. The laboratories process, store and distribute human cell based products and gene therapies for transplantation and other therapies. CMT consists of seven laboratories based within NHSBT facilities at Barnsley, Birmingham, Filton (Bristol), Liverpool, Oxford and Southampton. Currently, these laboratories require scheduled and adhoc deep cleans of their clean rooms, with frequencies detailed in Appendix 1. Each laboratory operates clean room facilities in accordance with EUGMP (Annex 1) requirements and is licensed by the Human Tissue Authority (HTA) in accordance with the Human Tissue (Quality and Safety for Human Application) Regulations 2007 and the Joint Accreditation Committee - ISCT and EBMT (JACIE). The activities of the NHSBT CMT stem cell processing laboratories involve processing, testing, storage and distribution of human progenitor cells for autologous and/or allogeneic transplantation. Liverpool, Barnsley, CBC, Birmingham and Filton laboratories are also regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) for cell and gene therapy medicinal product manufacture. A high level of hygiene and cleanliness is essential to preventing contamination and maintaining the sterility of these products. Additional information: A pre-market engagement meeting will take place early 2026, all interested parties will receive an on-line invite.

Tender statusplanning
STAGE-DATE LEDGER

Reported dates, without an invented lifecycle.

The current projection contains one award release, not a verified chain of planning, tender, award, contract and modification records. Dates are shown in source-field order and are not silently repaired.

  1. 01Notice publishedPublication timestamp on the held release9 Dec 2025
SUPPLIER EVIDENCE

Published names and exact identifiers

A company profile appears only when this release carries a usable company number. Name-only suppliers remain name-only.

No supplier is named in this projection. That does not prove the notice had no supplier in every source version.

SOURCE

Contracts Finder release

Published 9 Dec 2025 · held through the daily award projection · Open Government Licence v3.0.

Inspect the official JSON release ↗